To investigate whether Elac2 mutations can predispose to prostate tumorigenesis and model a “two‐hit hypothesis” tumorigenesis scenario, we used TRAMP mice where the Pb promoter expresses SV40 large‐T and small‐t antigens in the prostatic epithelium (Greenberg et al, 1994) to initiate progressive prostatic neoplasia with hyperplasia by 10 weeks of age and adenocarcinoma from 18 to 30 weeks of age (Gingrich et al, 1999). The gene discussed is ELAC2; the disease is hyperplasia.